Navigation Links
Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show

Study Presented at Second International Conference on Avian Influenza at France's Pasteur Institute

PARIS, June 01, 2007 /PRNewswire-FirstCall/ -- Very low doses of Novavax Inc.'s pandemic influenza vaccine provided protection against a lethal challenge of live H5N1 viruses, according to pre-clinical data presented here today at the Second International Conference on Avian Influenza in Humans.

The data show that two 0.6 microgram doses of Novavax's virus-like particle (VLP) H5N1 vaccine -- without the addition of an adjuvant -- protected ferrets from challenges with live H5N1 bird flu viruses. This dose is 25 fold lower than the average human dose for most seasonal flu vaccines and more than 100 times lower than other H5N1 vaccines against avian influenza. Novavax plans to submit an investigational new drug application to the U.S. Food and Drug Administration in mid-2007 to commence human clinical trials with the novel H5N1 influenza vaccine.

"We are extremely encouraged that even very low doses of our vaccine are proving to be effective in pre-clinical models without the need for adjuvants," said Dr. Rick Bright, Novavax's Vice President of Global Influenza Programs. "This may be important in a pandemic, where the vaccine supply could possibly need to be 'stretched' to meet the significant global demand."

In the study, ferrets were inoculated with a range of doses of the company's VLP vaccine made from an Indonesian strain of H5N1 avian influenza. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live H5N1 virus, and all survived. The typical human dose of a seasonal influenza vaccine is 15 micrograms. Other pandemic vaccines with no adjuvant have shown only modest levels of immunogenicity in humans with doses as high as 90 micrograms. In this study, ferrets received either 15, 3 or 0.6 micrograms of Novavax's vaccine, and all immun
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
2. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
3. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
4. Rapid Response was Crucial to Containing the 1918 Flu Pandemic
5. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
8. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
9. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
10. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
(Date:5/5/2015)... , May 5, 2015  CipherHealth, a leading ... providers improve patient care, sent representatives to the Nepalese ... sending five of their nurses to Nepal ... the catastrophic earthquake last month. In addition to helping ... donation will be utilized for much-needed medical supplies for ...
(Date:5/5/2015)... , May 5, 2015   InspireMD, Inc. (NYSE ... protection systems, announced today that it will release its full ... on Monday, May 11 th before the open, followed ... its financial results and business outlook. Participants should ... (412) 542-4135 (International) and request the InspireMD call. A live ...
(Date:5/5/2015)... 2015  Trovagene, Inc. (NASDAQ:  TROV), a developer ... results for the three months ended March 31, ... we presented favorable clinical results at ASCO GI, ... our Precision Cancer Monitoring platform,s ability to detect ... lung cancers," said Antonius Schuh, Ph.D., chief executive ...
Breaking Medicine Technology:Five Nurses and Medical Supplies En Route to Nepal With Donation Assistance from CipherHealth 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6
(Date:5/5/2015)... Beverly Hills Cosmetic Dentist, Arthur Glosman released ... to be sold at the offices of Arthur Glosman DDS, ... worldwide through an online store . “I wanted to ... between dental care and beauty with a luxurious collection of ... Dr. Glosman. , Dr. Glosman’s Advanced Dental Health + ...
(Date:5/5/2015)... AxoGen, Inc. (NASDAQ: AXGN), a ... peripheral nerve repair market, reported record revenue of $4.95 ... compared to $3.14 million in the year-ago first quarter. ... portfolio of nerve repair products - Avance® Nerve ... and our solid sales execution delivered another record quarter ...
(Date:5/5/2015)... 2015 The global lab automation market ... $3,474.2 Million in 2014, at an estimated CAGR of ... lab automation market on the basis of equipment and ... On the basis of application, Lab Automation Market is ... proteomics solutions. Drug discovery is a major application of ...
(Date:5/5/2015)... Viverae®, a health management and engagement ... multinational developer, manufacturer and marketer of innovative, life-enhancing ... oncology and surgical specialty products, as the recipient ... Award recognizes outstanding achievement in the design and ... client base. , Viverae reviewed the employee wellness ...
(Date:5/5/2015)... Dr. Patricia George knows all too well the debilitating ... hypertension specialist at the University of Pittsburgh Medical Center ... initial idea entered her mind for Team PHenomenal Hope. ... the 2010 PHA International Conference,” George recalled. “The speakers ... their climb up Mt. Kilimanjaro and I remember thinking ...
Breaking Medicine News(10 mins):Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2
... the Board,s Strategy and Vote the BLUE Proxy Card Today ... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced that ... the Company,s Annual Meeting of Stockholders on May 27, 2009. ... Directors on the BLUE proxy card today and reject the ...
... Friends and Family of Iraq and ... YORK, May 1 To help ease the transition ... home, Iraq and Afghanistan Veterans of America (IAVA) joined the Ad ... advertisements (PSAs) for their Veteran Support Campaign. Launched on Veterans Day ...
... employers, patients and doctors on helping people with back pain ... 5 at the University of Leicester. , It is estimated ... a year with people taking time off work because of ... with healthcare but due to lost work production and associated ...
... role in shoulder tendon tearsROSEMONT, Ill., May 1 People ... are at increased risk of similar tendon tears ... issue of The Journal of Bone and Joint ... predisposition as a possible cause for rotator cuff disease," said ...
... News) -- Dr. Charles Ericsson, head of clinical infectious disease ... to HealthDay about what scientists know right now ... the swine flu? , "Swine influenza is a known ... through mutations, it can acquire the ability to attack humans," ...
... Heart Association ATVB Conference Shows Reduction in Non-Calcified Plaque ... and SAN FRANCISCO, May 1 VIA Pharmaceuticals, Inc. ... of a sub-study of patients in its acute coronary ... slice multidetector computed tomography (MDCT) scans before and after ...
Cached Medicine News:Health News:Amylin Sends Letter to Shareholders 2Health News:Amylin Sends Letter to Shareholders 3Health News:Amylin Sends Letter to Shareholders 4Health News:Amylin Sends Letter to Shareholders 5Health News:Amylin Sends Letter to Shareholders 6Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 2Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 3Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 4Health News:New guidance on making work less of a pain in the back 2Health News:Rotator Cuff Tears: Are They All in the Family? 2Health News:Rotator Cuff Tears: Are They All in the Family? 3Health News:Swine Flu: A Primer 2Health News:Swine Flu: A Primer 3Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 3Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 4Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: